CoChat

Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists

Nauck, Michael A, Horowitz, Michael · 2023 · The Lancet

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(23)01201-1

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 12 references

Cited by

See all 17

Metadata

Authors
Nauck, M. A., & Horowitz, M.
Affiliations
  • Universitätsmedizin Greifswald (DE)
  • Royal Adelaide Hospital (AU)
Corresponding author
Nauck, Michael A
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-08
Volume
402
Issue
10400
Pages
429-431
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4381893369
Cited by
16
References
12
Citations by year
2026: 7 · 2025: 7 · 2024: 2
FWCI
3.00
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
orforglipron, GLP-1 receptor agonists, oral drug delivery, once-daily dosing, type 2 diabetes, glycemic control, weight loss, cardiovascular adverse events, exenatide, liraglutide, dulaglutide, semaglutide
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists. https://app.cochat.ai/papers/10.1016/s0140-6736(23)01201-1
The paper
Nauck, M. A., & Horowitz, M. (2023). Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists. The Lancet. https://doi.org/10.1016/s0140-6736(23)01201-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.